RT Journal Article
T1 Circulating levels of sclerostin are associated with cardiovascular mortality.
A1 Novo-Rodríguez, Cristina
A1 García-Fontana, Beatriz
A1 Luna-Del Castillo, Juan De Dios
A1 Andújar-Vera, Francisco
A1 Ávila-Rubio, Verónica
A1 García-Fontana, Cristina
A1 Morales-Santana, Sonia
A1 Rozas-Moreno, Pedro
A1 Muñoz-Torres, Manuel
AB Cardiovascular diseases are a health problem throughout the world, especially in people with diabetes. The identification of cardiovascular disease biomarkers can improve risk stratification. Sclerostin is a modulator of the Wnt/β-catenin signalling pathway in different tissues, and it has recently been linked to vascular biology. The current study aimed to evaluate the relationship between circulating sclerostin levels and cardiovascular and non-cardiovascular mortality in individuals with and without type 2 diabetes. We followed up a cohort of 130 participants (mean age 56.8 years; 48.5% females; 75 with type 2 diabetes; 46 with prevalent cardiovascular disease) in which serum sclerostin levels were measured at the baseline. Time to death (both of cardiovascular and non-cardiovascular causes) was assessed to establish the relationship between sclerostin and mortality. We found that serum sclerostin concentrations were significantly higher in patients with prevalent cardiovascular disease (p
YR 2018
FD 2018-06-21
LK http://hdl.handle.net/10668/12626
UL http://hdl.handle.net/10668/12626
LA en
DS RISalud
RD Apr 6, 2025